← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Parmedics, Inc.
Temecula, CA
$2,564,793
Total funding
4
Grants
Funding over time
peak $878.4K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,564,793 · 4
By mechanism
R44$1,671,055 · 1
R41$893,738 · 3
Investigators at Parmedics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma$878,390
R44 · FY2024 · HL
Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma$792,665
R44 · FY2025 · HL
Protease-activated-receptor-2 antagonists for treatment of migraine pain$310,351
R41 · FY2023 · NS
Development of small molecule Protease-activated-receptor-2 antagonists as oral asthma therapeutics$300,000
R41 · FY2023 · HL
Development of Small Molecule Antagonists of PAR-2 for treatment of asthma$283,387
R41 · FY2021 · HL